amfAR, The Foundation for AIDS Research

amfAR Supports FDA Approval of Pre-Exposure Prophylaxis (PrEP), Urges Demonstration Projects to Determine Implementation

Truvada was studied in several major trials that demonstrated the once-daily pill can significantly reduce the chances of acquiring HIV

For Immediate Release   

Media Contact:
Cub Barrett, Program Communications Manager|
(212) 806-1602

NEW YORK, July 16, 2012—amfAR, The Foundation for AIDS Research on Monday announced its support of the FDA’s decision to approve use of the antiretroviral drug Truvada as an option for HIV prevention.

The decision follows a May 10 recommendation by an advisory panel to the agency, which said that Truvada, currently approved for HIV treatment, is also a safe and effective means to prevent infection in sexually active adults. The drug, manufactured by Gilead Sciences Inc., was studied in several major trials that demonstrated the once-daily pill, when taken consistently, significantly reduces the chances of acquiring HIV.

As part of a coalition of AIDS advocacy organizations, amfAR called on the FDA earlier this year to approve Truvada as PrEP, and, in testimony before the advisory panel, emphasized the need for demonstration projects to determine how PrEP can be used for optimal public health impact. The coalition of groups has called on the government to immediately enact policy measures and education initiatives to ensure those who could most benefit from PrEP have access to it.

“Now that the FDA has approved Truvada as part of a comprehensive approach to reduce HIV infection rates in the U.S. and globally, we need to quickly determine how we’re going to incorporate it into our prevention strategies and goals,” said amfAR CEO Kevin Robert Frost. “We know that Truvada, when taken as directed, works. Now we need to figure out how to properly use it to change the course of the epidemic.”

“We need to use multiple combined approaches to bring HIV incidence down in the U.S. and globally,” said Chris Collins, amfAR’s vice president and director of public policy. “While our ultimate goal is to find a cure for HIV, PrEP offers us a tool we can use today to prevent new infections among those most at risk.”

About amfAR 

amfAR, The Foundation for AIDS Research, is one of the world’s leading nonprofit organizations dedicated to the support of AIDS research, HIV prevention, treatment education, and the advocacy of sound AIDS-related public policy. Since 1985, amfAR has invested more than $366 million in its programs and has awarded grants to more than 2,000 research teams worldwide.